Form 8-K - Current report:
SEC Accession No. 0001628280-22-028167
Filing Date
2022-11-03
Accepted
2022-11-03 16:01:31
Documents
14
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20221103.htm   iXBRL 8-K 42544
2 EX-99.1 exhibit-991110322.htm EX-99.1 92116
6 GRAPHIC logoa.gif GRAPHIC 43773
  Complete submission text file 0001628280-22-028167.txt   344447

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20221103.xsd EX-101.SCH 1941
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20221103_lab.xml EX-101.LAB 24132
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20221103_pre.xml EX-101.PRE 12545
8 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20221103_htm.xml XML 11309
Mailing Address 7000 MARINA BLVD BRISBANE CA 94005
Business Address 7000 MARINA BLVD BRISBANE CA 94005 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 221357803
SIC: 2836 Biological Products, (No Diagnostic Substances)